Mounjaro BNF UK Guide | From £135.00 | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro BNF UK Price From £124.99

Get Mounjaro at the cheapest UK price from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

WEIGHTLOSSNEW £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Your BNF Mounjaro Questions Answered

Published on: June 03, 2026

Searching for reliable mounjaro BNF UK online pharmacy information? At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance on Mounjaro (tirzepatide), including BNF classification, prescribing criteria, and dosing schedules. Mounjaro is available from £124.99 following a free online consultation with our UK prescribers.

Mounjaro BNF Classification and Licensing

In the British National Formulary (BNF), Mounjaro (tirzepatide) is classified under section 6.1.2.3 as a glucagon-like peptide-1 (GLP-1) receptor agonist, though it uniquely activates both GIP and GLP-1 receptors [1]. The Medicines and Healthcare products Regulatory Agency (MHRA) licensed Mounjaro in the UK in September 2023 for weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity.

Unlike single-pathway GLP-1 receptor agonists such as semaglutide, tirzepatide's dual mechanism produces enhanced metabolic effects. In the SURMOUNT-1 trial, participants achieved an average body weight reduction of 20.9% at the 15 mg dose over 72 weeks, compared to 2.4% with placebo [1]. This dual-agonist approach represents a significant advancement in obesity pharmacotherapy available through UK prescribers.

BNF Dosing Schedule for Mounjaro

The BNF recommends a gradual dose escalation schedule to minimise gastrointestinal side effects. Treatment begins with 2.5 mg subcutaneously once weekly for four weeks, increasing to 5 mg for the next four weeks [2]. Your UK prescriber will then assess tolerance and efficacy before considering further increases to 7.5 mg, 10 mg, 12.5 mg, or the maximum maintenance dose of 15 mg.

Each dose escalation occurs at four-week intervals, allowing your body to adapt to the medication's effects. This graduated approach significantly reduces the incidence of nausea and vomiting compared to rapid titration [2]. Our superintendent pharmacist Tarun Kumar ensures all dispensed doses align with current BNF guidance and your prescriber's specific recommendations.

Adjusting Your Mounjaro Dose

If you experience persistent gastrointestinal side effects, your prescriber may delay dose escalation by an additional four weeks. The BNF notes that remaining at a lower dose does not compromise treatment efficacy — clinical trials demonstrated meaningful weight loss across all maintenance doses [2]. Never adjust your dose without consulting your UK prescriber, as this may affect both safety and treatment outcomes.

Mounjaro Side Effects: BNF Guidance

The BNF lists gastrointestinal disturbances as the most common side effects of tirzepatide, occurring in more than 10% of patients. These include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [3]. In clinical trials, these effects were typically mild to moderate in severity and diminished over time as patients adapted to treatment.

Less common but significant side effects include acute pancreatitis, gallbladder disorders, and hypoglycaemia (particularly when used with other glucose-lowering medicines). The BNF advises prescribers to counsel patients on recognising signs of pancreatitis — persistent severe abdominal pain radiating to the back — and to discontinue treatment immediately if suspected [3]. Our UK clinical team reviews your full medical history during consultation to identify any contraindications before prescribing.

Managing Common Side Effects

To minimise nausea and gastrointestinal discomfort, the BNF recommends eating smaller, more frequent meals and avoiding high-fat foods during the initial weeks of treatment. Staying well-hydrated and administering your injection at a consistent time each week may also improve tolerance. If side effects persist beyond the first month or significantly impact your quality of life, contact your prescriber to discuss dose adjustment or alternative treatments.

Treatment BNF Classification Administration Starting Price
Mounjaro (tirzepatide) Dual GIP/GLP-1 agonist Once weekly injection From £124.99
Wegovy (semaglutide) GLP-1 receptor agonist Once weekly injection From £69.00
Saxenda (liraglutide) GLP-1 receptor agonist Daily injection From £68.00
Orlistat Lipase inhibitor Three times daily oral From £32.00
Xenical (orlistat) Lipase inhibitor Three times daily oral From £32.00

BNF Prescribing Criteria for Mounjaro

According to BNF guidance, Mounjaro should only be prescribed as part of a comprehensive weight management programme that includes dietary modification and increased physical activity [4]. UK prescribers must verify that patients meet specific BMI thresholds: 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea.

The BNF recommends discontinuing treatment if patients do not achieve at least 5% body weight loss after 16 weeks at the maximum tolerated dose. This ensures appropriate use of NHS and private healthcare resources whilst prioritising patient safety [4]. At Cured Pharmacy, our UK prescribers conduct thorough clinical assessments to ensure you meet these criteria before approving your prescription.

Mounjaro Contraindications in the BNF

The BNF lists several absolute contraindications for tirzepatide, including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 [5]. Mounjaro is also contraindicated in patients with severe gastrointestinal disease, including gastroparesis and inflammatory bowel disease, as it may exacerbate these conditions.

Pregnancy and breastfeeding are additional contraindications, as animal studies demonstrated potential foetal harm and it remains unknown whether tirzepatide passes into breast milk [5]. Women of childbearing potential should use effective contraception during treatment and discontinue Mounjaro at least two months before planned conception. Our online consultation form specifically screens for these contraindications to ensure safe prescribing.

Drug Interactions to Consider

The BNF notes that tirzepatide delays gastric emptying, which may affect the absorption of oral medications. This is particularly relevant for medicines with narrow therapeutic windows, such as warfarin and levothyroxine [5]. If you take oral contraceptives, the BNF recommends using additional barrier methods for four weeks after starting Mounjaro or increasing the dose. Your UK prescriber will review all current medications during your consultation to identify potential interactions.

Comparing Mounjaro with Other BNF Weight Loss Treatments

The BNF currently lists several pharmacological options for weight management, each with distinct mechanisms and efficacy profiles. Whilst Mounjaro demonstrates superior weight loss outcomes in head-to-head trials, alternative treatments may be more suitable depending on your medical history, tolerance, and budget considerations.

Injectable GLP-1 receptor agonists like semaglutide (available as Wegovy) and liraglutide (Saxenda) work through similar pathways but with single-receptor activity. Oral options include orlistat, which reduces dietary fat absorption by approximately 30% and may be preferred by patients who wish to avoid injections [6]. Your UK prescriber will discuss these alternatives during your consultation to identify the most appropriate treatment for your circumstances.

When to Consider Alternative Treatments

If you experience persistent side effects with Mounjaro despite dose adjustment, or if the medication proves cost-prohibitive for long-term use, several BNF-listed alternatives offer effective weight management support. Semaglutide-based treatments provide robust efficacy with once-weekly dosing, whilst daily liraglutide injections allow more flexible dose titration. Oral orlistat requires no prescription for the lower 60 mg dose and may suit patients seeking non-injectable options with lower upfront costs.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
  3. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078 [accessed 13 August 2026]
  4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity [ID6259]. NICE Technology Appraisal Guidance. https://www.nice.org.uk/guidance/indevelopment/gid-ta11235 [accessed 13 August 2026]
  5. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/14443/smpc [accessed 13 August 2026]
  6. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and must be prescribed following appropriate clinical evaluation.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What is Mounjaro's BNF classification?
Mounjaro is classified in BNF section 6.1.2.3 as a GLP-1 receptor agonist, though it uniquely activates both GIP and GLP-1 receptors. This dual mechanism distinguishes it from single-pathway alternatives like semaglutide.
What is the BNF-recommended starting dose for Mounjaro?
The BNF recommends starting Mounjaro at 2.5 mg subcutaneously once weekly for four weeks, then increasing to 5 mg. Further dose escalations occur at four-week intervals based on tolerance and efficacy, up to a maximum of 15 mg weekly.
Does the BNF list any contraindications for Mounjaro?
Yes, the BNF lists personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, pregnancy, and breastfeeding as contraindications. Your UK prescriber will screen for these during consultation.
What are the most common Mounjaro side effects in the BNF?
The BNF lists nausea, diarrhoea, vomiting, constipation, and abdominal discomfort as very common side effects, occurring in more than 10% of patients. These typically diminish over time with continued treatment and gradual dose escalation.
Can I get Mounjaro without a prescription in the UK?
No, Mounjaro is a prescription-only medicine in the UK and requires clinical assessment by a UK-registered prescriber. At Cured Pharmacy, you complete a free online consultation which our prescribers review before approving your prescription.
How does Mounjaro compare to Wegovy according to the BNF?
Both are BNF-listed GLP-1 treatments for weight management, but Mounjaro's dual GIP/GLP-1 mechanism typically produces greater weight loss than Wegovy's single-pathway semaglutide. Your prescriber will recommend the most suitable option based on your medical history and treatment goals.
What BNF guidance exists for stopping Mounjaro treatment?
The BNF recommends discontinuing Mounjaro if patients do not achieve at least 5% body weight loss after 16 weeks at the maximum tolerated dose. Your UK prescriber will monitor your progress and discuss alternative treatments if necessary.
Are there any BNF drug interactions with Mounjaro?
Yes, the BNF notes that Mounjaro delays gastric emptying, potentially affecting absorption of oral medications including warfarin, levothyroxine, and oral contraceptives. Your prescriber will review all current medications during consultation to identify potential interactions.
Is Mounjaro listed in the BNF for weight loss?
Yes, Mounjaro (tirzepatide) is listed in the British National Formulary (BNF) under drugs used in obesity as a licensed treatment for weight management in adults with a BMI of 30 or above, or 27 with weight-related conditions. Cured Pharmacy follows BNF guidance when prescribing Mounjaro to ensure safe, evidence-based treatment for all eligible patients.
How does the BNF dosing schedule work for Mounjaro?
The BNF recommends starting Mounjaro at 2.5mg once weekly for four weeks, then increasing to 5mg, with further dose escalations every four weeks as tolerated up to a maximum of 15mg. This gradual titration helps minimise side effects and allows your body to adjust. Cured Pharmacy follows this BNF-approved dosing schedule to ensure safe and effective treatment tailored to your progress.
Can I check Mounjaro interactions in the BNF before ordering?
Yes, the BNF provides detailed information on Mounjaro drug interactions, including effects on oral medications due to delayed gastric emptying. It's important to review these before starting treatment. When you order from Cured Pharmacy, our UK-registered prescribers will check all your medications against BNF guidance to ensure Mounjaro is safe for you.
Does Cured Pharmacy follow BNF guidelines for Mounjaro prescribing?
Absolutely, Cured Pharmacy strictly adheres to BNF prescribing guidelines for Mounjaro to ensure your safety and treatment efficacy. Our UK-registered clinicians assess your eligibility based on BMI, medical history, and contraindications as outlined in the BNF. This ensures you receive the cheapest UK price without compromising on clinical standards or regulatory compliance.
What BNF cautions apply to Mounjaro use in the UK?
The BNF lists cautions for Mounjaro including history of pancreatitis, diabetic retinopathy, and concurrent use with other weight-loss medications. It also advises caution in patients over 75 years due to limited data. Cured Pharmacy's online consultation process screens for all BNF-listed cautions to ensure Mounjaro is appropriate and safe for you before dispensing.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.